ATS 2024 Final Program

Click on the session title to view the speakers

311

WEDNESDAY • MAY 22

8:42 The Racialized Impacts of Making Care Illegal or Difficult 8:51 Do No Harm: Survival Tips for Clinicians in an Impossible Situation 9:05 Good Trouble Indiana on How To Fight New Threats to Clinical Autonomy 9:14 The Ripple Effect of Dobbs: Changing the Conversation in the UK and Ireland 9:23 Question and Answer CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE D3 INTERSTITIAL LUNG ABNORMALITIES: MOVING THE NEEDLE TOWARDS THERAPEUTIC CLINICAL TRIALS Assembly on Clinical Problems 8:15 a.m. - 9:45 a.m. Marriott Marquis San Diego Marina Grand Ballroom 8-9 (Lobby Level, North Tower) Target Audience Clinicians who care for patients at risk for developing interstitial lung abnormalities and interstitial lung disease (ILD) Clinical and translational researchers interested in methods of early detection, diagnosis and treatment of ILA and ILD Objectives At the conclusion of this session, the participant will be able to: • improve understanding of ILA, its classification, and features of radiologic ILA progression • learn about potential methods to further evaluate ILA and risk of progression, such as radiologic features, serum biomarkers, and optical imaging modalities with capabilities to assess and identify microscopic features of ILA not visible by CT • learn new information about steps needed for the conduct of therapeutic clinical trials, which will be needed to inform future clinical management and follow-up for patients with ILA In this session, we will discuss interstitial lung abnormalities (ILA), their role as an identifiable precursor to symptomatic pulmonary fibrosis, and the potential use of existing and novel technologies to get the field closer to therapeutic clinical trials in ILA cohorts. We will discuss the steps and tools needed for conduct of therapeutic clinical trials in ILA, the pros and cons of screening for ILA, and novel biologic and imaging biomarkers

BEHAVIORAL • CLINICAL • TRANSLATIONAL CRITICAL CARE TRACK

D2 A NEW REALITY FOR CRITICAL CARE AFTER DOBBS Assemblies on Critical Care; Behavioral and Health Services Research; Ethics and Conflicts of Interest Committee 8:15 a.m. - 9:45 a.m. San Diego Convention Center Room 7A-B (Upper Level) Target Audience Bedside ICU physicians and nurses, including CCM trainees; healthcare policy makers; patient advocates; and any clinicians and scientists interested in obstetric critical care, healthcare policy, and healthcare access and equity. Objectives At the conclusion of this session, the participant will be able to: • update their differential diagnoses of life-threatening complications stemming from reduced access to abortion; the implications that has for therapy; and the ways that may disproportionately impact racialized patients • develop concrete skills in navigating the conflict between patient needs and barriers to access to standard care imposed by either hospital institutional risk avoidance or true legal barriers • identify specific actions pulmonary and critical care clinicians and researchers can take to advocate for and improve their colleagues and their patients’ safety Since the Supreme Court’s Dobbs’ ruling in 2022, state abortion prohibitions have led to increased morbidity for pregnant patients, including life-threatening sepsis, and a growing body of research raises concerns for critically ill pregnant patients under these restrictions. This symposium will address the post-Dobbs critical care landscape: first hearing from a patient who needed urgent obstetric care in a state that banned access to that care, attendees will then learn how to manage clinical emergencies patients and providers face, navigate the moral and legal challenges providers confront, and participate in work being done to keep our patients and providers safe. 8:15 The Rapidly Changing Landscape of Abortion Care 8:28 Managing Life-threatening Complications, Maternal Critical Illness, and Decreased Access to Abortion

ATS 2024 • San Diego, CA